January 8, 2018 / 1:40 PM / Updated 11 minutes ago BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln Reuters Staff 
Jan 8 (Reuters) - Immunomedics Inc: 
* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION 
* IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION 
* IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE 
* IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020 Source text for Eikon: Further company coverage: